BioCentury
ARTICLE | Company News

Hospira, Medicines Co. cardiovascular news

July 13, 2015 7:00 AM UTC

The U.S. Court of Appeals for the Federal Circuit ruled that two patents covering Angiomax bivalirudin from The Medicines Co. are invalid. The Medicines Co. had filed suit against Hospira in August 2010 after Hospira submitted two ANDAs seeking to market its generic bivalirudin before the two patents, U.S. Patents Nos. 7,582,727 and 7,598,343, expire on July 27, 2028. The Medicines Co. reported $95.1 million in U.S. sales of Angiox in 1Q15 and $599.5 million in 2014. The Medicines Co. said it is evaluating its options, and Hospira did not respond to inquiries. ...